| 000 | 01769 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515211517.0 | ||
| 264 | 0 | _c20101207 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1460-2393 | ||
| 024 | 7 |
_a10.1093/qjmed/hcq017 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTesta, L | |
| 245 | 0 | 0 |
_aWhat is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. _h[electronic resource] |
| 260 |
_bQJM : monthly journal of the Association of Physicians _cJun 2010 |
||
| 300 |
_a367-77 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review; Systematic Review | ||
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 |
_aHemorrhage _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPiperazines _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 | _aPrasugrel Hydrochloride |
| 650 | 0 | 4 | _aPurinergic P2 Receptor Antagonists |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aReceptors, Purinergic P2 _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aThiophenes _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTiclopidine _xanalogs & derivatives |
| 700 | 1 | _aBhindi, R | |
| 700 | 1 | _aVan Gaal, W J | |
| 700 | 1 | _aLatini, R A | |
| 700 | 1 | _aPizzocri, S | |
| 700 | 1 | _aLanotte, S | |
| 700 | 1 | _aBiondi Zoccai, G G L | |
| 700 | 1 | _aValgimigli, M | |
| 700 | 1 | _aLaudisa, M L | |
| 700 | 1 | _aBrambilla, N | |
| 700 | 1 | _aBanning, A P | |
| 700 | 1 | _aBedogni, F | |
| 773 | 0 |
_tQJM : monthly journal of the Association of Physicians _gvol. 103 _gno. 6 _gp. 367-77 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/qjmed/hcq017 _zAvailable from publisher's website |
| 999 |
_c19578960 _d19578960 |
||